Grail investors urged to act by Aug 4 deadline in NHS-Galleri fraud suit
Grail, Inc. investors who bought shares between May 13, 2025, and February 19, 2026, must act by August 4, 2026, to become lead plaintiffs in a class action alleging fraud regarding the NHS-Galleri trial. The lawsuit claims executives hid internal data showing the three-year follow-up period was insufficient, leading to a 50.55% stock drop and $2.2 billion market cap loss after the trial failed to meet its primary endpoint.
*this image is generated using AI for illustrative purposes only.
Investors in Grail, Inc. (NASDAQ: GRAL) who purchased shares between May 13, 2025, and February 19, 2026, must act by August 4, 2026, to seek appointment as lead plaintiff in a securities class action lawsuit. The litigation, captioned Robbins v. Grail, Inc., No. 26-cv-05428, is pending in the U.S. District Court for the Northern District of California and alleges that the company misled shareholders about the viability of its NHS-Galleri cancer screening trial. The case seeks to recover losses stemming from a $2.2 billion market capitalization wipeout after the trial failed to meet its primary endpoint. This deadline is critical for investors wishing to influence the direction of the case, which concerns alleged violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5.
Allegations of Concealed Trial Limitations
The complaint asserts that Grail and certain senior executives misrepresented the clinical design and progress of the NHS-Galleri trial, which aimed to demonstrate a statistically significant reduction in late-stage (Stage III and IV) cancer diagnoses. Defendants allegedly claimed the study was optimally structured with a three-year follow-up period to achieve this endpoint. However, the lawsuit contends that internal data from the first screening round indicated the three-year timeframe was insufficient. Rather than disclosing these adverse trendlines, management allegedly withheld granular data, citing the need to protect "the integrity of the trial" and "the interest of the participants," while continuing to promote favorable top-line results.
Hagens Berman Sobol Shapiro LLP, which is actively investigating the matter, has focused its inquiry on when Grail management first recognized that the required follow-up period diverged from the touted three-year duration. Reed Kathrein, the Hagens Berman partner leading the investigation, stated the firm is examining whether the company selectively promoted favorable top-line results while ignoring internal indicators suggesting the timeline was flawed.
Key dates in the alleged timeline of misrepresentations include:
- May 13, 2025: Positive top-line results announced; detailed positive predictive value (PPV) numbers withheld.
- August 12, 2025: Statistical powering of the trial confirmed as sufficient, with no disclosure of adverse internal findings.
- September 9, 2025: NHS-Galleri promoted as targeting late-stage cancer reduction.
- October 20, 2025: Success of Pathfinder 2 cited to reinforce confidence in NHS-Galleri outcomes.
- November 12, 2025: Q3 earnings call repeated high-PPV messaging without updated risk disclosures.
- February 19, 2026: Primary endpoint failure revealed; stock price collapsed.
Market Impact and Financial Fallout
On February 19, 2026, Grail announced that the NHS-Galleri trial did not meet its primary endpoint, admitting it "probably should have allowed for a longer follow-up period." The disclosure caused Grail's stock price to decline $51.32 per share, or 50.55%, on February 20, 2026, erasing over $2.2 billion in market capitalization.
| Metric | Detail |
|---|---|
| Closing Price (Feb 19) | $101.53 |
| Closing Price (Feb 20) | $50.21 |
| Share Price Decline | 50.55% |
| Value Lost per Share | $51.32 |
| Market Cap Loss | Over $2.2 billion |
Legal Proceedings and Investor Rights
Under the Private Securities Litigation Reform Act of 1995, the court appoints a lead plaintiff to represent all class members. The lead plaintiff selects counsel and oversees litigation strategy. Investors who purchased GRAL stock during the class period may apply to serve as lead plaintiff by August 4, 2026. The court generally appoints the applicant with the largest financial interest in the relief sought. Lead plaintiffs are not required to pay fees or costs; securities class actions are prosecuted on a contingency basis.
Multiple law firms are urging investors to submit their claims. The Rosen Law Firm, represented by Laurence Rosen and Phillip Kim, is actively soliciting investors, emphasizing its track record in securities litigation. Hagens Berman Sobol Shapiro LLP, Pomerantz LLP, Berger Montague PC, Bleichmar Fonti & Auld LLP, Bernstein Liebhard LLP, Levi & Korsinsky LLP, Faruqi & Faruqi LLP, Robbins Geller Rudman & Dowd LLP, Holzer & Holzer, LLC, Bragar Eagel & Squire, P.C., Schall, Brown & Schwartz LLP, and The Gross Law Firm are also encouraging eligible investors to discuss their legal rights. Attorneys Ken Dolitsky and Michael Albert of Robbins Geller Rudman & Dowd LLP are specifically contacting investors with substantial losses. Marshall P. Dees, Esq., of Holzer & Holzer, LLC, is also encouraging eligible investors to discuss their legal rights. Additionally, Bragar Eagel & Squire, P.C. partners Brandon Walker and Melissa Fortunato are directly contacting investors who suffered losses, providing contact information via telephone at (212) 355-4648 and email at investigations@bespc.com . Schall, Brown & Schwartz LLP partners Brian Schall, Andrew Brown, and David Schwartz are inviting investors to discuss their rights free of charge via phone at 310-301-3335 or email at info@schallfirm.com . Bleichmar Fonti & Auld LLP is also soliciting investors, noting its recent recoveries including over $900 million from Tesla, Inc.’s Board of Directors and $420 million from Teva Pharmaceutical Ind. Ltd. The Gross Law Firm is also seeking investors, directing them to contact dg@securitiesclasslaw.com or call (646) 453-8903. Investors who do not seek lead plaintiff appointment by the deadline are not excluded from the case and retain the right to participate in any settlement or judgment.
How might the outcome of the lead plaintiff appointment influence Grail's willingness to settle the class action versus proceeding to trial?
What are the potential implications for Grail's R&D strategy and future clinical trial designs following the NHS-Galleri endpoint failure?
Could this litigation trigger a broader regulatory review of how biotech companies disclose interim data and trial design limitations to investors?
15
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
